Fellowship · Royal Oak, MI
Sponsored by Corewell Health
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
Journal of hepatology · 2024 · 87 citations · Stuart Gordon
Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B.
Journal of hepatology · 2025 · 46 citations · Stuart Gordon
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hepatology (Baltimore, Md.) · 2023 · 108 citations · Stuart Gordon
TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis.
Cancer medicine · 2023 · 74 citations · Ihab Kassab
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial.
The lancet. Gastroenterology & hepatology · 2026 · 12 citations · Stuart Gordon
ASGE guideline on the role of endoscopy in the management of malignant hilar obstruction.
Gastrointestinal endoscopy · 2021 · 83 citations · Laith Jamil
ASGE guideline on the role of endoscopy in the management of benign and malignant gastroduodenal obstruction.
Gastrointestinal endoscopy · 2021 · 85 citations · Laith Jamil
Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · 84 citations · Stuart Gordon